Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis - Test2 - elhamkhani - TriplyDB

Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis

Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis

http://www.wikidata.org/entity/Q34586319

about

From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms Early phase clinical trials to identify optimal dosing and safety Preclinical mouse cancer models: a maze of opportunities and challenges.Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma.Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma Genetically engineered mouse models of PI3K signaling in breast cancer.Identification and characterization of poorly differentiated invasive carcinomas in a mouse model of pancreatic neuroendocrine tumorigenesis.Quantum dot-based quantitative immunofluorescence detection and spectrum analysis of epidermal growth factor receptor in breast cancer tissue arrays.OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5.Controlling escape from angiogenesis inhibitors.PTEN loss in the continuum of common cancers, rare syndromes and mouse models.Mechanisms of mTOR inhibitor resistance in cancer therapy.Contemporary management of nonfunctioning pancreatic neuroendocrine tumors.Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy.Therapy innovation for the treatment of pancreatic neuroendocrine tumors.Signalling pathways passing Src in pancreatic endocrine tumours: relevance for possible combined targeted therapies.Translation of molecular pathways into clinical trials of neuroendocrine tumors.Sunitinib in pancreatic neuroendocrine tumors.Everolimus for the treatment of pancreatic neuroendocrine tumors.Novel molecular targets for the treatment of gastroenteropancreatic endocrine tumors: answers and unsolved problems Sunitinib malate for the treatment of pancreas malignancies--where does it fit?The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation.Current understanding of the molecular biology of pancreatic neuroendocrine tumors.Therapeutic gene delivery using bioreducible polymers.Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets.Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling.An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs).Medical treatment of gastroenteropancreatic neuroendocrine tumors.Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis.Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations.Image-based 3D modeling study of the influence of vessel density and blood hemoglobin concentration on tumor oxygenation and response to irradiation.Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.

P2860

Q26822011-669D4783-3EBE-4A97-864E-09666BD89F2B Q26862544-0600D7C9-D089-436D-B521-29E3CD348A11 Q26865076-1631FC9E-602B-4914-B557-DE1D6CEC105A Q27322080-71046EE8-6D6E-4972-98CE-280471C16CAE Q30472055-C0A17B8D-6F1C-4FAA-9246-663731A65ACA Q30559275-6F8CBEB6-7DB0-47E8-A23E-3F83F10CF17A Q34206363-67A98D96-F0F3-4F4A-BD29-0A71062EFDD3 Q34332175-C079535B-4DB4-44D0-8953-3B18694D45BA Q34731699-5AA8984F-3793-465C-BBCD-5E0ED7592B65 Q35487994-43B847AA-7580-4BC7-AE5A-3D5078ABFD42 Q36413415-D12601AA-061B-414E-8BCD-6F9DCFEA968E Q36694132-98B7EF05-244C-49A2-8F0B-7236DE3D84E1 Q37091117-3F6A17A5-A5F2-453D-9CC9-636F7C017C94 Q37097257-4320ACD5-C3FE-47AE-96C4-EB66184059AB Q37327558-3AF92D0E-9F40-4262-B3BA-7D806CAE98BC Q37672654-09E7F63D-2F5E-4AAF-9095-B082BFB9D3BC Q37856722-3C076D15-251C-4F58-8E35-1170AC46C0FA Q37872670-A11EE40B-B89B-4690-9462-58DEA1BF9F94 Q37947138-3E8FE333-A97D-4E30-8E6A-AAF66EC6BAA8 Q37981893-2F42394D-E256-461D-8A59-54A1AC487419 Q37988905-60890E7E-C9EB-40A2-9829-C3531ACFFD8E Q37996268-9CB5CAE2-522D-4E44-9815-1CB000DE1C8A Q38003074-2E56AF10-725F-4A9A-9C3C-3CB7C1B570A4 Q38015764-E2E11193-E55B-4F2E-985A-1D27C0B1C954 Q38032923-520B9322-7765-4C95-89DD-6974AB7999DB Q38076275-510E2E9B-91EE-4E6D-B7AC-D762BFB4E103 Q38086310-3636DA3D-70EA-481C-B913-240199B3098D Q38099268-4EDA1BBA-7E28-47B1-9CCF-8DC5754FF67F Q38120515-50491E8D-17F0-4FE4-A0E4-8FD26631010C Q38157750-330A7942-9A4E-4BE0-885E-78CBF5A85878 Q38174515-53F62072-A256-4F05-9DA5-D536406924FB Q38174516-C3D13EF4-D527-4758-B328-214A71ACA9C0 Q38773966-F12BD19D-9E8E-479B-BAB4-07F359B49986 Q38835123-115C958C-6770-4D46-907C-0EB332F84128 Q39254045-41B7F7E2-882F-4F42-BC50-B91D13D05086 Q39328713-E5414441-111C-4ECD-8EFC-6CDFFB23FDC2 Q39735943-FE1B92DA-0DE4-479F-AAEE-5DF21D730599 Q42576027-25B87043-558B-4D99-92E6-2151929A71E6 Q46336461-86AD1C1D-4740-49AF-AEB1-AF7E2F6DF68D Q47393972-5DE4BD57-5929-41EF-B013-B1C1A0702985

P2860

Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis

http://www.wikidata.org/entity/Q34586319

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Survival benefit with proapopt ...... neuroendocrine carcinogenesis

@ast

Survival benefit with proapopt ...... neuroendocrine carcinogenesis

@en

Survival benefit with proapopt ...... neuroendocrine carcinogenesis

@nl

type

label

Survival benefit with proapopt ...... neuroendocrine carcinogenesis

@ast

Survival benefit with proapopt ...... neuroendocrine carcinogenesis

@en

Survival benefit with proapopt ...... neuroendocrine carcinogenesis

@nl

prefLabel

Survival benefit with proapopt ...... neuroendocrine carcinogenesis

@ast

Survival benefit with proapopt ...... neuroendocrine carcinogenesis

@en

Survival benefit with proapopt ...... neuroendocrine carcinogenesis

@nl

P1433

Q34586319-E4DF0CFC-218B-4372-BC74-670D6268CCD7

P1476

Q34586319-8D633E2F-E011-4657-87A7-B01A3B36EA60

P2093

Q34586319-7B512272-C59B-41BB-938B-C799B18FE4E0

Q34586319-CDB0216D-3625-4ADC-AA2E-0733D744D382

P2860

Q34586319-024084D4-CE7F-4C76-9882-A36FC29FAF98

Q34586319-03226168-2592-455F-942E-E52DACC7333C

Q34586319-0C74FDAC-E534-497B-B980-165D4E827CCF

Q34586319-130AF9B6-F655-4BF3-B0AF-4D55E457E7BA

Q34586319-158BAC13-FF40-4BCE-A6F9-8786F6C6DE61

Q34586319-1BCA394A-63E5-4D21-B697-9ABAEBDC9170

Q34586319-1CA5ED09-FB69-490C-8186-48896AC341B4

Q34586319-238EE019-C400-4A08-87E8-C7064296EADE

Q34586319-285E27B8-5DC5-43DF-BBCE-10CAFA4B6EE8

Q34586319-2A38D7D3-764B-4D39-AC44-7F8631173F86

P304

Q34586319-E59B6B3E-2FAC-427F-81AC-76D63B68DEC4

P31

Q34586319-11A80C24-BC32-4B74-855B-9E3AA0D8A0AE

P356

Q34586319-78BEEFFC-FE15-46E5-85DD-D8EE13A0E2D1

P407

Q34586319-1C96A56D-E36A-4BE9-9DF7-BC09AEBEEBFB

P433

Q34586319-8F1AD5C1-5F43-4AF5-BBB1-9E5C21AD5607

P478

Q34586319-993D984E-FD53-4CA4-97ED-6AA1782635E2

P50

Q34586319-35C33348-1585-4DD6-B830-98ACF26A7A12

P577

Q34586319-281A5E55-033D-4BFE-8EEA-B6C592CD274E

P5875

Q34586319-8D6F10AF-43E6-4BFC-807B-7665D01EC01C

P698

Q34586319-5CFBCF10-D156-4D2E-8419-A46B6C5500B0

P932

Q34586319-91650113-5EBA-471C-B422-4703AC9BDF3C

P356

JCO.2010.28.0198

P1433

Journal of Clinical Oncology

P1476

Survival benefit with proapopt ...... neuroendocrine carcinogenesis

@en

P2093

Christopher W Chiu

http://www.w3.org/2001/XMLSchema#string

Hiroaki Nozawa

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

Targeting the mTOR signaling network for cancer therapy

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

EGFR antagonists in cancer treatment

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Localization, dynamics, and function of survivin revealed by expression of functional survivinDsRed fusion proteins in the living cell.

The applicability of mTOR inhibition in solid tumors.

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

P304

4425-4433

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.28.0198

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Douglas Hanahan

P577

2010-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46170144

http://www.w3.org/2001/XMLSchema#string

P698

20823411

http://www.w3.org/2001/XMLSchema#string

P932

3041788

http://www.w3.org/2001/XMLSchema#string